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First-line Chemotherapy
Before the introduction of targeted therapy in advanced
non-small-cell lung cancer (NSCLC), systemic che-
motherapy was the only modality available for pa-
tients whose disease status did not allow curative-
intent surgery or radiotherapy. Platinum-based
combination chemotherapy has become the standard
of care for physically fit patients, since publication of
a meta-analysis in 1995 and the American Society of
Clinical Oncology guidelines in 1997.1,2 Advances
have been made in recent years regarding the selection
of first-line chemotherapy regimens. Large-scale,
randomized studies have found that different regimens
may have little impact on patient survival, as long as a
platinum-based compound and a third-generation
chemotherapeutic agent (e.g. paclitaxel, docetaxel,
vinorelbine, gemcitabine, irinotecan) are included
in the 2-drug regimen.3 For patients with good
performance status (Eastern Cooperative Oncology
Group [ECOG] score 0 or 1), monotherapy or triple-
therapy schedules are not recommended, although
monotherapy may be appropriate for patients with
poor performance status.
Second-line Chemotherapy
Most patients who receive first-line chemotherapy will
eventually progress and face the question of whether
second-line chemotherapy should be given. Several
large, randomized studies of second-line regimens
have been completed. Docetaxel 75 mg/m2 adminis-
tered 3 times weekly was superior to best supportive
care in terms of overall survival; it was also superior
(although not statistically significantly) to docetax-
el 100 mg/m2, vinorelbine or ifosfamide regarding
1-year survival.4,5 In recent guidelines from the
American Society of Clinical Oncology,6 docetaxel
monotherapy was recommended as the second-line
treatment for advanced NSCLC patients who had
already received chemotherapy. Further, pemetrexed
is a novel antimetabolite that has a demonstrable
effect as second-line therapy for NSCLC. A recent,
randomized study showed that pemetrexed had simi-
lar efficacy to docetaxel as a second-line treatment
for NSCLC, but with much less treatment-related
toxicity, especially hematotoxicity.7
Third-line Chemotherapy
With improvements in chemotherapy, more patients
survive, after having received at least 2 treatment
regimens, than was previously the case. Indeed,
gefitinib demonstrated a reasonable response rate
and toxicity profile as a third-line treatment in the
Iressa® Dose Evaluation for Advanced Lung Cancer
(IDEAL)-1 study.8 Erlotinib was superior to placebo
in terms of survival in advanced NSCLC patients who
had failed first- or second-line treatment.9 These
novel, targeted treatments against epidermal growth
factor receptors were a big breakthrough for heavily
pretreated lung-cancer patients. However, not all
patients can benefit from these drugs. It is reasonable
to offer third-line chemotherapy to patients with
good performance status if a specific schedule has
demonstrated safety and efficacy in clinical trials.
Unfortunately, such trials of third-line schedules are
lacking. Only anecdotal reports exist in the literature,
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response rates have generally been low, and survival
has not been clearly described.
In this issue of the journal, Chen et al propose a
regimen for patients with advanced NSCLC who have
already received chemotherapy.10 Weekly gemcitabine
was given to 20 patients as second-line (n = 3) or third-
line treatment (n = 17). Two patients who received gem-
citabine as third-line treatment responded, asso-
ciated toxicities were acceptable, and responses and
survival times were similar to those reported for weekly
gemcitabine used as second-line treatment. The authors
concluded that third-line therapy with weekly
gemcitabine is effective, has limited toxicity, and can
be considered for patients who require chemotherapy
after failure of 1 or 2 previous regimens.
Patients who are able to receive third-line che-
motherapy are often exposed to many cycles of tox-
ic drugs, and thus often have damaged bone marrow
and nervous systems, and compromised renal and
hepatic function. Therefore, only compounds with a
wide therapeutic window can be considered, and
weekly gemcitabine is one such schedule with low
systemic toxicity. In addition, cancer patients always
develop resistance to chemotherapeutic agents after
long-term exposure, and cross-resistance between
chemotherapeutic agents may be important, particularly
if a compound with a similar mechanism of action to
that of a previous regimen constituent is used in a
subsequent treatment schedule. Thus, if gemcitabine
has not been used previously, it is probably the best
monotherapy choice among the 5 third-generation
chemotherapies; indeed, 3 of these chemotherapies
(paclitaxel, docetaxel and vinorelbine) share similar
mechanisms of action (microtubule inhibition) and
resistance (p-glycoprotein over-expression).
Chemotherapy remains the mainstay of treatment
for advanced NSCLC in this era of targeted treatment,
and clinical oncologists continue to explore any
potential treatment advances that can be provided to
patients. Consequently, third-line chemotherapy is
given to many patients with advanced NSCLC. It is
now time to generate evidence to show that third-line
chemotherapy is indeed helpful to such patients. Based
on anecdotal observations of efficacy for such che-
motherapy reported in this issue of the journal,10 a
formal trial of third-line chemotherapy in NSCLC
should be designed and conducted. Potential investi-
gators should be encouraged to perform a multi-
center trial with the assistance of a cancer group such
as the Taiwan Cooperative Oncology Group.
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